Literature DB >> 31138453

A simple and rapid assay to evaluate purity of foot-and-mouth disease vaccine before animal experimentation.

Hyejin Kim1, Ah-Young Kim2, Jae-Seok Kim2, Jung-Min Lee2, Hye-Young Lee3, Kwang-Myun Cheong3, Byounghan Kim2, Choi-Kyu Park4, Young-Joon Ko5.   

Abstract

Currently, foot-and-mouth disease (FMD) vaccine purity is tested in cattle to detect antibodies against the non-structural protein (NSP) after repeated immunization with the final vaccine product. In case of vaccine failure, the manufacturing company would suffer significant economic loss. To prevent such unfortunate losses with the final vaccine product, in vitro testing is required to quantitate an NSP antigen during the manufacturing process prior to animal experiments. A novel lateral-flow assay device was developed using a monoclonal antibody (MAb) against the 3B NSP. To determine the minimal amount of NSP required to elicit antibodies in livestock, goats were immunized several times with various concentrations of either the recombinant 3AB (rec.3AB) protein or FMD virus culture supernatant. Antibodies against 3AB were elicited after a second immunization with 10.6 ng to 42.5 ng of rec.3AB and a third immunization with a 10-fold diluted FMD virus culture supernatant in goats. The lateral-flow assay device detected the minimal amount of rec.3AB and native NSP in FMD virus culture supernatant required to induce NSP antibodies in goats. The in vitro assay device is simple and economical, provides rapid results, and should be useful for FMD vaccine-manufacturing companies prior to conducting animal experiments to test the vaccine purity.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Assay; Foot-and-mouth disease; Nonstructural proteins; Purity; Vaccine

Year:  2019        PMID: 31138453     DOI: 10.1016/j.vaccine.2019.05.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Determination of non-structural protein level for Turkey foot-and-mouth disease vaccine antigens during in-process.

Authors:  Beyhan Sareyyüpoğlu; Can Çokçalışkan; Aydın Çoskuner; Veli Gülyaz
Journal:  Clin Exp Vaccine Res       Date:  2020-07-31

2.  Foot-and-Mouth Disease Virus Evades Innate Immune Response by 3C-Targeting of MDA5.

Authors:  Hyejin Kim; Ah-Young Kim; Jieun Choi; Sun Young Park; Sang Hyun Park; Jae-Seok Kim; Sim-In Lee; Jong-Hyeon Park; Choi-Kyu Park; Young-Joon Ko
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.